Pioglitazone for Oral Premalignant Lesions

NCT00951379 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

52

Enrollment

NIH

Sponsor class

Stopped Due to slow accrual.

Conditions

Oral Leukoplakia

Interventions

DRUG: Pioglitazone hydrochloride
OTHER: placebo
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)